Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826713 | 0.79 | LPL (0.40) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL22886631 | 0.78 | LPL (0.39) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL13906124 | 0.74 | — | — | |
| SCHEMBL14746261 | 0.73 | LPL (0.36) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL12703333 | 0.73 | LPL (0.42) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL5134635 | 0.72 | F11 (0.38) | LPLLIPGP2RX7KDM4ECA1 | |
| SCHEMBL23031438 | 0.71 | LPL (0.40) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL13905386 | 0.71 | KDM4E (0.32) | KDM4ELMNAALOX5 | |
| SCHEMBL12566009 | 0.71 | LPL (0.37) | LPLLIPGP2RX7 | |
| SCHEMBL5899734 | 0.70 | LPL (0.54) | LPLLIPGP2RX7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | Genosco Inc. | 2024-11-14 | — | — | US | disclosed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| CN-118666828-A | Triazine compound and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-12064426-B2 | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | Genosco Inc. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-117903140-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117136186-A | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | 盖诺斯克公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2009032653-A1 | INHIBITORS OF AKT ACTIVITY | SMITH KLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032653-A1 | INHIBITORS OF AKT ACTIVITY | SMITH KLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032651-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032651-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032652-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032652-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064426-B2 | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | ROCK2, ROCK1, MYLK3 | LPL 4675/4885LIPG 2908/4885P2RX7 4381/4885 |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | LPL 295/4885LIPG 1458/4885P2RX7 213/4885 |
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | LPL 3809/4885LIPG 4263/4885P2RX7 1783/4885 |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | LPL 4054/4885LIPG 3519/4885P2RX7 9/4885 |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | LPL 4054/4885LIPG 3519/4885P2RX7 9/4885 |
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | ROCK2, ROCK1, MYLK3 | LPL 4709/4885LIPG 2967/4885P2RX7 4438/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | LPL 4054/4885LIPG 3519/4885P2RX7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.